Jimenez Freddy A. 4

What Happened
Freddy Jimenez, SVP & General Counsel of Celldex Therapeutics (CLDX), received a grant of 93,000 derivative securities on June 25, 2026. The Form 4 reports a price of $0.00 and classifies the transaction as an award/grant (code A); a footnote states this represents an option granted under Celldex’s 2021 Omnibus Equity Incentive Plan. No cash changed hands in this reported transaction.

Key Details

• Transaction date: 2026-06-25; filing received: 2026-06-29 (appears to be timely).
• Reported amount: 93,000 derivative shares; reported price: $0.00.
• Vesting: 25% vests on June 25, 2027; the remainder vests quarterly in equal amounts over the following 12 quarters (per footnote).
• Shares owned after transaction: Not stated in the summary provided / not reported in the excerpt.
• Footnotes: F1 = option granted under the 2021 Omnibus Equity Incentive Plan; F2 = detailed vesting schedule above.
• Transaction type: Award/grant of an equity derivative (option), not an open-market buy or sale — not an immediate cash investment or disposition.

Context
This was an executive equity award, which is a common form of long-term compensation. For retail investors, awards are routine and subject to vesting — they do not represent an immediate purchase of shares or sale proceeds. The award gives the holder the right to acquire shares in the future according to the stated vesting schedule.